CYP-LAD
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (May 2008) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
CYP-LAD
|
|
| Systematic (IUPAC) name | |
| (6aR,9R)-N,N-diethyl-7-cyclopropyl-4,6,6a,7,8,9- hexahydroindolo-[4,3-fg]quinoline-9-carboxamide |
|
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C22H27N3O |
| Mol. mass | 349.48 g/mol |
| Synonyms | CYP-LAD, 6-cyclopropyl-6-nor-Lysergic acid diethylamide |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Controlled in the US via the Federal Analog Act |
| Routes | Oral |
CYP-LAD, also known as 6-cyclopropyl-6-nor-lysergic acid diethylamide, is an analogue of LSD.
CYP-LAD has been sold by some research chemical suppliers but might be considered illegal in some countries due to its structural similarity to LSD.
|
|||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
